000119981 001__ 119981
000119981 005__ 20240319081026.0
000119981 0247_ $$2doi$$a10.3389/fcimb.2022.977944
000119981 0248_ $$2sideral$$a130366
000119981 037__ $$aART-2022-130366
000119981 041__ $$aeng
000119981 100__ $$aCasado, Javier
000119981 245__ $$aTwo-component regulatory systems in Helicobacter pylori and Campylobacter jejuni: attractive targets for novel antibacterial drugs
000119981 260__ $$c2022
000119981 5060_ $$aAccess copy available to the general public$$fUnrestricted
000119981 5203_ $$aTwo-component regulatory systems (TCRS) are ubiquitous signal transduction mechanisms evolved by bacteria for sensing and adapting to the constant changes that occur in their environment. Typically consisting of two types of proteins, a membrane sensor kinase and an effector cytosolic response regulator, the TCRS modulate via transcriptional regulation a plethora of key physiological processes, thereby becoming essential for bacterial viability and/or pathogenicity and making them attractive targets for novel antibacterial drugs. Some members of the phylum Campylobacterota (formerly Epsilonproteobacteria), including Helicobacter pylori and Campylobacter jejuni, have been classified by WHO as “high priority pathogens” for research and development of new antimicrobials due to the rapid emergence and dissemination of resistance mechanisms against first-line antibiotics and the alarming increase of multidrug-resistant strains worldwide. Notably, these clinically relevant pathogens express a variety of TCRS and orphan response regulators, sometimes unique among its phylum, that control transcription, translation, energy metabolism and redox homeostasis, as well as the expression of relevant enzymes and virulence factors. In the present mini-review, we describe the signalling mechanisms and functional diversity of TCRS in H. pylori and C. jejuni, and provide an overview of the most recent findings in the use of these microbial molecules as potential novel therapeutic targets for the development of new antibiotics.
000119981 536__ $$9info:eu-repo/grantAgreement/ES/DGA/B25-20R$$9info:eu-repo/grantAgreement/ES/UZ/UZ2018-0420
000119981 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000119981 590__ $$a5.7$$b2022
000119981 592__ $$a1.308$$b2022
000119981 591__ $$aMICROBIOLOGY$$b28 / 135 = 0.207$$c2022$$dQ1$$eT1
000119981 593__ $$aMedicine (miscellaneous)$$c2022$$dQ1
000119981 591__ $$aIMMUNOLOGY$$b55 / 161 = 0.342$$c2022$$dQ2$$eT2
000119981 593__ $$aInfectious Diseases$$c2022$$dQ1
000119981 593__ $$aMicrobiology (medical)$$c2022$$dQ1
000119981 593__ $$aMicrobiology$$c2022$$dQ1
000119981 593__ $$aImmunology$$c2022$$dQ2
000119981 594__ $$a6.4$$b2022
000119981 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000119981 700__ $$0(orcid)0000-0001-5932-2889$$aLanas, Ángel$$uUniversidad de Zaragoza
000119981 700__ $$0(orcid)0000-0002-0531-0943$$aGonzález, Andrés$$uUniversidad de Zaragoza
000119981 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000119981 7102_ $$11002$$2060$$aUniversidad de Zaragoza$$bDpto. Bioq.Biolog.Mol. Celular$$cÁrea Bioquímica y Biolog.Mole.
000119981 773__ $$g12 (2022), 977944 [9 pp]$$tFrontiers in Cellular and Infection Microbiology$$x2235-2988
000119981 8564_ $$s1533378$$uhttps://zaguan.unizar.es/record/119981/files/texto_completo.pdf$$yVersión publicada
000119981 8564_ $$s2162303$$uhttps://zaguan.unizar.es/record/119981/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000119981 909CO $$ooai:zaguan.unizar.es:119981$$particulos$$pdriver
000119981 951__ $$a2024-03-18-16:45:18
000119981 980__ $$aARTICLE